Clinical and pathophysiological consequences of on-demand treatment with PPI in endoscopy-negative reflux disease. Is rebound hypersecretion of acid a problem?
- 9 December 2010
- journal article
- clinical trial
- Published by Taylor & Francis in Scandinavian Journal of Gastroenterology
- Vol. 46 (4) , 398-405
Abstract
Objective. Rebound acid hypersecretion after withdrawal of proton pump inhibitor (PPI) may lead to symptom aggravation and difficulties in withdrawing anti-reflux medication. The aim was to investigate pathophysiological and clinical consequences of on-demand treatment with PPI in patients with endoscopy-negative reflux disease. Material and methods. Twenty-six patients with endoscopy-negative reflux disease were investigated for rebound effects of lansoprazole 15 mg, used on-demand, maximum 4 capsules daily during a 6-month period. P-CgA and s-gastrin were measured before, at termination and 2 weeks after stopping treatment. Symptom score was performed the week before and the second week after treatment, 24-h pH-metry after both periods. Results. Median daily consumption of lansoprazole was 15.1 mg (95% CI: 10.5; 18.8). S-gastrin before treatment was 31.2 pmol/l, 54.8 at the end (p < 0.01), 31.7 two weeks after withdrawal. P-CgA was 16.7 u/l before treatment, 37.5 at the end (p < 0.01), 17.7 two weeks after withdrawal (p = 0.35). A positive correlation was found between total consumption of lansoprazole and CgA increase during treatment (r = 0.44 p = 0.03). There was a reduction in symptom score during the treatment period from 30 (24–38) before, to 20 (15–36) the second week after treatment, p = 0.06. 32% had increase in symptoms. Conclusions. Rebound acid hypersecretion is probably an infrequent problem in on-demand treatment with PPI in patients with endoscopy-negative reflux disease. A significant increase in p-CgA and s-gastrin was found after 6 months treatment. Fourteen days after withdrawal, CgA and gastrin returned to pretreatment levels. Overall, no aggravation of symptoms was found, but 1/3 experienced increased symptoms.Keywords
This publication has 17 references indexed in Scilit:
- Rebound acid hypersecretion from a physiological, pathophysiological and clinical viewpointScandinavian Journal of Gastroenterology, 2009
- Proton-Pump Inhibitor Therapy Induces Acid-Related Symptoms in Healthy Volunteers After Withdrawal of TherapyGastroenterology, 2009
- Systematic review: rebound acid hypersecretion after therapy with proton pump inhibitorsAlimentary Pharmacology & Therapeutics, 2006
- Rebound acid hypersecretion after long‐term inhibition of gastric acid secretionAlimentary Pharmacology & Therapeutics, 2004
- Endoscopy‐negative reflux disease: what is the value of a proton‐pump inhibitor test in everyday clinical practice?Scandinavian Journal of Gastroenterology, 2003
- Marked increase in gastric acid secretory capacity after omeprazole treatment.Gut, 1996
- The Glasgow Dyspepsia Severity Score ??? a tool for the global measurement of dyspepsiaEuropean Journal of Gastroenterology & Hepatology, 1996
- Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.Gut, 1991
- Temporary Cessation of Long-Term Maintenance Treatment with Omeprazole in Patients with H2-Receptor-Antagonist-Resistant Reflux OesophagitisScandinavian Journal of Gastroenterology, 1990
- Long-Term Omeprazole Treatment in Man: Effects on Gastric Endocrine Cell PopulationsDigestion, 1988